.svg){kind=small}
SLU-PP-332 is an experimental small molecule developed at Saint Louis University that targets Estrogen-Related Receptor Alpha (ERRα), a key nuclear receptor that controls mitochondrial biogenesis, fat oxidation, and cellular energy production. This compound is gaining traction in the world of longevity and metabolic optimization due to its unique ability to enhance metabolism without stimulating the central nervous system.
How SLU-PP-332 Works
SLU-PP-332 activates ERRα, which governs the expression of genes involved in:
- Mitochondrial respiration
- ATP synthesis
- Fatty acid β-oxidation
- Oxidative stress resilience
ERRα is especially active in energy-demanding tissues such as skeletal muscle, heart, brown adipose tissue, and liver. By upregulating this pathway, SLU-PP-332 enhances caloric burn, mitochondrial output, and cellular efficiency.
Benefits of SLU-PP-332
Based on preclinical studies, SLU-PP-332 shows promise in the following areas:
- Boosts Metabolic Rate
- Increases basal energy expenditure
- Promotes calorie burn without reducing appetite
- Enhances Mitochondrial Biogenesis
- Improves mitochondrial density and function in muscle and liver
- Supports better cellular energy output
- Improves Insulin Sensitivity
- May benefit individuals with type 2 diabetes or metabolic syndrome
- Supports Fat Loss
- Encourages fatty acid utilization and thermogenesis
- Works independently of stimulants or appetite suppressants
- Potential Neuroprotective & Anti-Aging Effects
- By enhancing mitochondrial function, may support longevity and cognitive health
Side Effects & Safety Considerations
As of now, the study data lists potential side effects based on its mechanism which include:
- Over-metabolism: Risk of unintentional weight loss or fatigue in lean individuals
- Liver stress: Due to upregulated mitochondrial turnover
- Hyperthyroid-like symptoms: In rare cases, due to increased energy uncoupling
- Unknown hormonal impacts: ERRα is related to estrogen signaling, though not directly estrogenic
Who Might Benefit from SLU-PP-332?
With more human trials, potential candidates could include:
- Individuals with obesity or metabolic syndrome
- People with chronic fatigue or long COVID
- Athletes and bodybuilders seeking non-stimulant metabolic enhancers
- Biohackers focused on mitochondrial optimization
- Those pursuing anti-aging and cellular longevity protocols
Research
- Saint Louis University Study (2023)
- Demonstrated increased energy expenditure and fat oxidation in mice
- Upregulation of ERRα targets in liver and skeletal muscle
- ERRα Literature
- Known to regulate mitochondrial energy output and oxidative metabolism
- Proposed therapeutic target for NAFLD, T2D, and age-related decline
- Comparison to PGC-1α / AMPK Pathways
- Similar end-targets as popular longevity interventions like exercise mimetics, metformin, and caloric restriction mimetics
Is SLU-PP-332 the Future of Metabolic Enhancement?
SLU-PP-332 is an exciting new molecule with the potential to redefine how we approach metabolism, fat loss, and energy production—all by targeting mitochondria at the gene level. While human studies are still forthcoming, the preclinical data are promising and mechanistically sound.
As the science evolves, SLU-PP-332 could emerge as a cornerstone in the toolkit for metabolic health, longevity, and performance.
It is available by prescription from our compounding pharmacy. There are 2 oral dosing options and it is normally taken twice a day.